A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2

S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, John Vetto, C. A. Seipp, C. Simpson

Research output: Contribution to journalArticle

84 Scopus citations

Abstract

A new approach to cancer therapy has been developed based on the adoptive transfer of autologous lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2). Forty-one patients with advanced cancer who have failed all standard treatments were treated in this experimental protocol. Fourteen patients experienced an objective regression of cancer, including one patients with metastatic melanoma who underwent a complete regression. Objective responses were seen in patients with colorectal cancer, renal cell cancer, melanoma, and lung adenocarcinoma. The sites of tumor regression included subcutaneous tissue, lung, and liver. The major side effect of therapy resulted from the administration of high-dose IL-2 and was manifested primarily as fluid retention, resulting in a generalized capillary permeability leak syndrome. This approach to adoptive immunotherapy represents a promising approach to the therapy of patients with metastatic cancer. Attempts to increase the potency and decrease the toxicity of therapy and extend this treatment to patients with smaller tumor burdens are in progress.

Original languageEnglish (US)
Pages (from-to)262-272
Number of pages11
JournalSurgery
Volume100
Issue number2
Publication statusPublished - 1986
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Surgery

Cite this

Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Vetto, J., ... Simpson, C. (1986). A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery, 100(2), 262-272.